News
1d
Zacks Investment Research on MSNGSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, ...
GSK PLC GSK shares slid 2.06% to £14.50 Wednesday, on what proved to be an all-around positive trading session for the stock ...
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
Dr. Stephana Julia Moss, an investigator at the Canadian Center for Vaccinology (CCfV), Dalhousie University, has been ...
Investing.com -- Shares of AstraZeneca (ST: AZN) and GlaxoSmithKline (LON: GSK) fell Tuesday after former U.S. President ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3d
Pharmaceutical Technology on MSNNICE approves GSK’s belantamab mafodotin for blood cancerNHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.
After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...
GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results